Clinical biochemistry最新文献

{"title":"Comment on the article titled “Serum cystatin C is associated with peripheral artery stiffness in patients with type 2 diabetes mellitus combined with chronic kidney disease”","authors":"Mehmet Ilkin Naharci","doi":"10.1016/j.clinbiochem.2023.110699","DOIUrl":"https://doi.org/10.1016/j.clinbiochem.2023.110699","url":null,"abstract":"","PeriodicalId":10172,"journal":{"name":"Clinical biochemistry","volume":"123 ","pages":"Article 110699"},"PeriodicalIF":2.8,"publicationDate":"2023-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138439431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The liver-heart axis in patients with severe obesity: The association between liver fibrosis and chronic myocardial injury may be explained by shared risk factors of cardiovascular disease","authors":"J. Young ,&nbsp;K.A. Seeberg ,&nbsp;K.M. Aakre ,&nbsp;H. Borgeraas ,&nbsp;N. Nordstrand ,&nbsp;T. Wisløff ,&nbsp;J. Hjelmesæth ,&nbsp;T. Omland ,&nbsp;J.K. Hertel","doi":"10.1016/j.clinbiochem.2023.110688","DOIUrl":"10.1016/j.clinbiochem.2023.110688","url":null,"abstract":"<div><h3>Background</h3><p>Severe obesity is associated with increased risk of non-alcoholic fatty liver disease and cardiovascular disease. We hypothesized that liver fibrosis as quantified by the Enhanced Liver Fibrosis (ELF) test would be predictive of myocardial injury and fibrosis, expressed by higher concentrations of cardiac troponin T and I measured by high-sensitivity assays (hs-cTnT and hs-cTnI, respectively).</p></div><div><h3>Material and methods</h3><p>We performed cross-sectional analyses of baseline data from 136 patients (mean age 45 years, 38 % male) with severe obesity participating in the non-randomized clinical trial <em>Prevention of Coronary Heart Disease in Morbidly Obese</em> Patients (ClinicalTrials.gov NCT00626964). Associations between ELF scores, hs-cTnT, and hs-cTnI concentrations were assessed using linear regression analysis.</p></div><div><h3>Results</h3><p>ELF scores were associated with hs-cTnT in the unadjusted model (B 0.381, 95 % Confidence Interval [CI] 0.247, 0.514), but the association was attenuated upon adjustment for potential confounders (B −0.031, 95 % CI −0.155, 0.093). Similarly, for hs-cTnI, an observed association with ELF scores in the unadjusted model was attenuated upon adjustment for potential confounders ((B 0.432, 95 % CI 0.179, 0.685) and (B 0.069, 95 % CI −0.230, 0.367), respectively). Age, sex, hypertension, and estimated glomerular filtration rate were amongst the shared predictors of ELF score, hs-cTnT, and hs-cTnI that provided the univariable models with the highest R-squared and lowest Akaike Information Criterion values.</p></div><div><h3>Conclusions</h3><p>Contrary to our hypothesis, ELF score did not predict myocardial injury and fibrosis, but rather demonstrated that an association between liver fibrosis and myocardial injury and fibrosis may be explained by shared risk factors of cardiovascular disease.</p></div>","PeriodicalId":10172,"journal":{"name":"Clinical biochemistry","volume":"123 ","pages":"Article 110688"},"PeriodicalIF":2.8,"publicationDate":"2023-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0009912023002163/pdfft?md5=80800b8b33b45e74987628fc7135ed91&pid=1-s2.0-S0009912023002163-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138298551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the CKD-EPI 2021 creatinine equation using laboratory data: Considerations for practice changes among clinical laboratories in British Columbia, Canada","authors":"Roy Yu-Wei Chen ,&nbsp;Junyan Shi","doi":"10.1016/j.clinbiochem.2023.110686","DOIUrl":"10.1016/j.clinbiochem.2023.110686","url":null,"abstract":"<div><h3>Introduction</h3><p>Clinical laboratories in British Columbia, Canada implemented the CKD-EPI 2009 equation without the race variable for estimated glomerular filtration rate (eGFR) reporting since 2014. As more clinical laboratories adopt the new CKD-EPI 2021 equation, the study aims to compare these two race-free CKD-EPI eGFR equations using the laboratory data from a large tertiary hospital in BC and evaluate the impact on reclassification of eGFR category.</p></div><div><h3>Methods</h3><p>Serum/plasma creatinine results and demographic data were collected from Vancouver General Hospital laboratory. The CKD-EPI 2009 without the race variable and CKD-EPI 2021 equations were computed. eGFR and its distributions were compared and reclassification of eGFR category was assessed across the full cohort and in specific patient populations.</p></div><div><h3>Results</h3><p>The analysis included 58,763 patients. The median age was 57 years, with women comprising 51 % of the population. The median of eGFR changed from 85 to 90 mL/min/1.73 m² using the CKD-EPI 2009 equation without the race variable and the CKD-EPI 2021 equation, respectively. The CKD-EPI 2021 equation reclassified 11.86 % of patients, mainly from G3a (45–59 mL/min/1.73 m²) to G2 (60–89 mL/min/1.73 m²). There was statistical significance between the non-renal and the renal population reclassified from G5 (&lt;15 mL/min/1.73 m²) to G4 (15–29 mL/min/1.73 m²).</p></div><div><h3>Conclusions</h3><p>Using laboratory data representative of local populations, we observed an overall positive shift to higher eGFR, with 11.86 % of individuals having improved eGFR categories based on the CKD-EPI 2021 equation. This study provides insights into clinical implications at both the individual and population levels. The data-based approach is the first step towards adopting the CKD-EPI 2021 equation within the province.</p></div>","PeriodicalId":10172,"journal":{"name":"Clinical biochemistry","volume":"123 ","pages":"Article 110686"},"PeriodicalIF":2.8,"publicationDate":"2023-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138294814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum levels of sonic hedgehog in patients with IgA nephropathy are closely associated with intrarenal arteriolar lesions","authors":"Fei Peng ,&nbsp;Lingling Wu ,&nbsp;Jie Wu ,&nbsp;Shuwei Duan ,&nbsp;Jiayi He ,&nbsp;Pu Chen ,&nbsp;Peng Wang ,&nbsp;Jiaona Liu ,&nbsp;Guangyan Cai ,&nbsp;Chuyue Zhang ,&nbsp;Xiangmei Chen","doi":"10.1016/j.clinbiochem.2023.110687","DOIUrl":"10.1016/j.clinbiochem.2023.110687","url":null,"abstract":"<div><h3>Background</h3><p>Intrarenal arteriolar disease is a major risk factor for poor prognosis in immunoglobulin A nephropathy (IgAN). The morphologic factor sonic hedgehog (SHH) plays an important role in a variety of vascular diseases, so it may be directly or indirectly involved in the process of renal arteriolar disease. The purpose of this study was to investigate the correlation between serum SHH levels and renal arteriole disease in patients with IgAN.</p></div><div><h3>Methods</h3><p>Subjects with primary IgAN diagnosed by renal biopsy performed between October 2018 and August 2019 at the First Medical Center of the Chinese PLA General Hospital were recruited. Blood specimens were collected from the patients within 1 week before renal biopsy after they signed an informed consent form, and healthy controls were recruited for blood specimen collection during the same period. The concentration of serum SHH was measured by enzyme-linked immunosorbent assay in this population.</p></div><div><h3>Results</h3><p>Serum SHH levels were significantly lower in the IgAN group than in the control group. 41 of the 94 subjects diagnosed with IgAN had severe renal arteriolosclerosis and, compared to their less severely affected counterparts, were older, more hypertensive, and characterized by lower levels of SHH, higher levels of tubular atrophy/interstitial fibrosis and a higher Lee's classification. Serum SHH concentration was found to be an independent predictor of severe intrarenal arteriolosclerosis in IgAN subjects after correction using multivariate analysis.</p></div><div><h3>Conclusion</h3><p>In this study, serum SHH levels were found to be significantly lower in patients with IgAN than in healthy subjects. Serum SHH may serve as a noninvasive biomarker of intrarenal arteriolosclerosis in patients with IgAN.</p></div>","PeriodicalId":10172,"journal":{"name":"Clinical biochemistry","volume":"123 ","pages":"Article 110687"},"PeriodicalIF":2.8,"publicationDate":"2023-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138290483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Methods of the PivotaL triAl of the Atellica VTLi point of care emergencY dePartment high sensitivity troponin evalUationS","authors":"W. Frank Peacock ,&nbsp;James L. Januzzi ,&nbsp;Femke de Theije ,&nbsp;Taylor Briseno ,&nbsp;Gary Headden ,&nbsp;Robert Birkhahn ,&nbsp;Brandon R. Allen ,&nbsp;Simon A. Mahler","doi":"10.1016/j.clinbiochem.2023.110679","DOIUrl":"10.1016/j.clinbiochem.2023.110679","url":null,"abstract":"<div><h3>Background</h3><p>The Atellica® VTLi point-of-care (POC) High Sensitivity Cardiac Troponin-I (hs-cTnI) assay is intended for use as an aid in the diagnosis of myocardial infarction (MI). Our primary objective is to assess its diagnostic performance in patients presenting with suspected acute coronary syndrome (ACS).</p></div><div><h3>Methods</h3><p>This prospective observational study will enrol ∼1500 patients at ∼20 U.S. Emergency Departments. After informed consent, adults (&gt;21 years of age) with suspected ACS, and no prior enrollment in this study, will provide a fingerstick and venous blood sample within 2 h of ED presentation, &gt;2 to ≤4 h, and &gt;4 to ≤9 h (max. blood draw = 60 mL). HEART and EDACS scores will be prospectively documented. Patients without the first blood draw may be enrolled if the second draw was obtained. Capillary and venous whole blood will undergo Atellica VTLi assay testing, with remaining venous sample processed to plasma and run. All results will be blinded to the clinical care team. Site operators will undergo a 3-day familiarization period. Quality control testing will be performed daily. At 30 ± 3 days, patient mortality status, major adverse cardiac events, and rehospitalizations will be determined. A clinical endpoint adjudication committee, blinded to hs-cTnI VTLi result, will define the final diagnosis. Sensitivity, specificity, and predictive values will describe the assay performance.</p></div><div><h3>Results</h3><p>We expect study completion within 114 weeks of enrollment of the first patient.</p></div><div><h3>Conclusions</h3><p>It is anticipated that the Atellica VTLi hs-cTnI assay validation study will define a performance equivalent to lab-based hs-cTnI, with results within ∼8 min at the point of care.</p></div>","PeriodicalId":10172,"journal":{"name":"Clinical biochemistry","volume":"121 ","pages":"Article 110679"},"PeriodicalIF":2.8,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0009912023002072/pdfft?md5=456935a8f038e2607d72bdd176dc75c6&pid=1-s2.0-S0009912023002072-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54227853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of elevated extracellular HSP72 in albuminuria with systemic inflammation and disease progression in type 2 diabetic kidney disease","authors":"Kuppuswami Jayashree ,&nbsp;Gandhipuram Periyasamy Senthilkumar ,&nbsp;Sreejith Parameswaran ,&nbsp;Mehalingam Vadivelan","doi":"10.1016/j.clinbiochem.2023.110682","DOIUrl":"10.1016/j.clinbiochem.2023.110682","url":null,"abstract":"<div><h3>Background</h3><p>Sub-clinical inflammation in hyperglycemia is tied to the pathogenesis of diabetic kidney disease (DKD). Though well known for its immunostimulatory function, the significance of extracellular heat shock protein 72 (eHSP72) in DKD is not well studied. We aimed to determine the association of extracellular HSP72 with systemic inflammation and the progression of DKD, and explore its possible clinical significance in DKD.</p></div><div><h3>Methods</h3><p>160 type 2 diabetic individuals were enrolled in the study. Their anthropometric data, routine biochemical parameters, urinary renal function parameters, and blood count parameters were estimated. Plasma from patients’ blood samples were used to estimate HSP72 and interleukin 1β (IL-1β) using sandwich immunoassays.</p></div><div><h3>Results</h3><p>Plasma eHSP72 is elevated in DKD. Pairwise comparisons showed the drastic elevation of eHSP72 in the presence of albuminuria. A significant positive relationship was observed between plasma levels of eHSP72 and IL-1β. eHSP72 levels did not statistically differ between micro and macro-albuminuric DKD. However, it was inversely associated with estimated glomerular filtration rate, the index of disease severity, independent of age, gender, diabetes duration and absolute monocyte count. At a cutoff of 0.52 ng/ml, with sensitivity of 64.1 % and specificity of 69.2 %, plasma eHSP72 differentiated the presence of DKD in type 2 diabetics with statistical significance.</p></div><div><h3>Conclusion</h3><p>The positive relationship of eHSP72 and IL-1β with worsening DKD likely indicates their participation in immunostimulatory pathways of renal fibrosis. eHSP72 may be closely linked to albuminuria-induced tubular injury and likely contributes to fibrotic changes in the progression of DKD. From our study, we infer the possible clinical significance of eHSP72 as a marker of sub-clinical renal damage in DKD, and the implication of IL-1β-associated mechanisms in DKD progression.</p></div>","PeriodicalId":10172,"journal":{"name":"Clinical biochemistry","volume":"121 ","pages":"Article 110682"},"PeriodicalIF":2.8,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71478559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Do not report estimated average glucose (eAG) from HbA1c: Evidence is emerging","authors":"Yu Chen","doi":"10.1016/j.clinbiochem.2023.110677","DOIUrl":"10.1016/j.clinbiochem.2023.110677","url":null,"abstract":"","PeriodicalId":10172,"journal":{"name":"Clinical biochemistry","volume":"121 ","pages":"Article 110677"},"PeriodicalIF":2.8,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49688929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical utility – Information about the usefulness of tests","authors":"Tony Badrick ,&nbsp;Francis Bowling","doi":"10.1016/j.clinbiochem.2023.110656","DOIUrl":"10.1016/j.clinbiochem.2023.110656","url":null,"abstract":"<div><p>The clinical utility of a diagnostic test refers to its usefulness in improving patient outcomes, informing clinical decision-making, and optimizing healthcare resources. A diagnostic test with high clinical utility provides accurate, reliable, and actionable information that can guide appropriate treatment decisions, monitor treatment response, and identify potential adverse events or complications.</p><p>Ultimately, the clinical utility of a diagnostic test depends on how well it can improve patient outcomes by guiding appropriate treatment decisions, improving clinical outcomes, and optimizing healthcare resource utilization. Healthcare providers need to weigh the benefits and drawbacks of using a particular diagnostic test in their clinical practice to determine its clinical utility.</p></div>","PeriodicalId":10172,"journal":{"name":"Clinical biochemistry","volume":"121 ","pages":"Article 110656"},"PeriodicalIF":2.8,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41100810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lack of observed interference by therapeutic monoclonal antibodies in select commonly utilized immunoassays","authors":"Kornelia D. Galior ,&nbsp;Paula M. Ladwig ,&nbsp;Melissa R. Snyder ,&nbsp;Alicia Algeciras-Schimnich ,&nbsp;Joshua A. Bornhorst ,&nbsp;Darci R. Block ,&nbsp;Nikola A. Baumann ,&nbsp;Maria Alice V. Willrich","doi":"10.1016/j.clinbiochem.2023.110685","DOIUrl":"https://doi.org/10.1016/j.clinbiochem.2023.110685","url":null,"abstract":"<div><h3>Background</h3><p>Therapeutic monoclonal antibodies (tmabs) have been hypothesized to interfere with immunoassay measurements, although studies investigating this potential new class of interference are lacking. This study evaluated the effects of tmabs used in cancers ipilimumab (Bristol Myers Squibb), nivolumab (Bristol Myers Squibb), pembrolizumab (Merck) and autoimmune disorders adalimumab (AbbVie), infliximab (Janssen) and vedolizumab (Takeda) in common immunoassays used in the clinical laboratory.</p></div><div><h3>Methods</h3><p>Residual sera from 10 randomly chosen patients were split into two tubes and spiked with same volume (approximately 5 % final volume) of either saline (control) or 6 tmabs (final concentration of 100 μg/mL each). Concentrations from sixteen analytes in 19 different assays were assessed: TSH (Roche and Beckman), free thyroxine (Roche and Siemens), cortisol (Beckman), Cancer Antigens (CA): CA19-9 (Beckman), CA15-3 (Roche), CA125 (Roche), and CA27.29 (Siemens), carcinoembryonic antigen (Beckman), alpha-fetoprotein (Beckman), thyroglobulin (Beckman) and thyroglobulin antibodies (Beckman), thyroid peroxidase antibody (Beckman), beta-human chorionic gonadotropin (Roche and Beckman), total prostate-specific antigen (Roche), parathyroid hormone (Roche) and antinuclear antibodies IgG (Werfen). The tmab spiked residual sera were compared with matched saline spiked sera and percent error was assessed against allowable total error defined from biological variation or CLIA limits.</p></div><div><h3>Results</h3><p>None of the tested immunoassays were affected by the presence of the tmabs, in samples within or outside assay reference intervals. The median % error among all immunoassays ranged between −2.0% (for TSH) to 2.7% (for TPO Ab assay).</p></div><div><h3>Conclusion</h3><p>These findings demonstrate no detectable tmab interference for the assessed immunoassays using spiked preparations of the tmabs in residual human sera. The findings are limited to the tmabs and immunoassays studied here.</p></div>","PeriodicalId":10172,"journal":{"name":"Clinical biochemistry","volume":"121 ","pages":"Article 110685"},"PeriodicalIF":2.8,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134655840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Age specific reference intervals for plasma biomarkers of neurodegeneration and neurotrauma in a Canadian population","authors":"Jennifer G. Cooper ,&nbsp;Sophie Stukas ,&nbsp;Mohammad Ghodsi ,&nbsp;Nyra Ahmed ,&nbsp;Ramon Diaz-Arrastia ,&nbsp;Daniel T. Holmes ,&nbsp;Cheryl L. Wellington","doi":"10.1016/j.clinbiochem.2023.110680","DOIUrl":"10.1016/j.clinbiochem.2023.110680","url":null,"abstract":"<div><h3>Introduction</h3><p>In this study, we aimed to create reference intervals (RI) using a large Canadian population-based cohort, for plasma protein biomarkers with potential utility to screen, diagnosis, prognosticate and manage a variety of neurological diseases and disorders. RIs were generated for: the ratio of amyloid beta 42 over 40 (Aβ42/40), phosphorylated tau-181 (p-tau-181), neurofilament light (NfL), and glial fibrillary acidic protein (GFAP).</p></div><div><h3>Methods</h3><p>900 plasma specimens from male and female participants aged 3–79 years old were obtained from the Statistics Canada Biobank, which holds specimens from the Canadian Health Measures Survey. Analysis of Aβ42/40, p-tau-181, NfL and GFAP was performed on the Quanterix Simoa HD-X analyzer using the Neurology 4-plex E and p-tau-181 assays. Discrete RIs were produced according to Clinical Laboratory Standards Institute guidelines (EP28-A3c). Continuous RIs were created using quantile regression.</p></div><div><h3>Results</h3><p>For discrete RIs, significant age partitions were determined for each biomarker. No significant sex partitions were found. The following ranges and age partitions were determined: Aβ42/40: 3–&lt;55y = 0.053–0.098, 55–&lt;80y = 0.040–0.090; p-tau-181: 3–&lt;12y = 1.4–5.6 pg/ml, 12–&lt;60y = 0.8–3.1 pg/ml, 60–&lt;80y = 0.9–4.0 pg/ml; NfL: 3–&lt;40y = 2.6–11.3 pg/ml, 40–&lt;60y = 4.6–17.7 pg/ml, 60–&lt;80y = 8.1–47.1 pg/ml; GFAP; 3–&lt;10y = 47.0–226 pg/ml, 10–&lt;60y = 21.2–91.9 pg/ml, 60–&lt;80y = 40.7–228 pg/ml. Continuous RIs produced smooth centile curves across the age range, from which point estimates for each year of age were calculated.</p></div><div><h3>Conclusions</h3><p>Discrete and continuous RIs for neurological plasma biomarkers will help refine normative cut-offs across the lifespan and improve the precision of interpretating biomarker levels. Continuous RIs are recommended for use in age groups, such as pediatrics and older adults, that experience rapid concentration changes by age.</p></div>","PeriodicalId":10172,"journal":{"name":"Clinical biochemistry","volume":"121 ","pages":"Article 110680"},"PeriodicalIF":2.8,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54227852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}